DST and melanoma: Applying these criteria, the positive rates of serum anti-BPAG1 auto-antibodies were 23.6% in total melanoma patients (13/55), 33.3% in early stage melanoma patients (6/18), and 18.9% in advanced stage melanoma patients (7/37) (Table 1).